Reason for request
Re-assessment of the Actual Benefit and Improvement in Actual Benefit in accordance with article R-163-21 of the Social Security Code.
Clinical Benefit
| Substantial |
The Actual Benefit of XEROQUEL LP in the treatment of schizophrenia is substantial. |
Clinical Added Value
| no clinical added value |
XEROQUEL LP does not provide an Improvement in Actual Benefit (IAB level V) compared with other treatments available in this indication. |
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
E5wg4EDjABH20ete
Listen
